MGRX
Income statement / Annual
Last year (2023), Mangoceuticals, Inc.'s total revenue was $731,493.00,
an increase of 8,083.16% from the previous year.
In 2023, Mangoceuticals, Inc.'s net income was -$9.21 M.
See Mangoceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$731,493.00
|
$8,939.00
|
$0.00
|
| Cost of Revenue |
$299,992.00 |
$4,089.00 |
$0.00 |
| Gross Profit |
$431,501.00 |
$4,850.00 |
$0.00 |
| Gross Profit Ratio |
0.59 |
0.54 |
0 |
| Research and Development
Expenses |
$0.00
|
$0.00
|
$0.00
|
| General & Administrative
Expenses |
$6.45 M
|
$2.00 M
|
$70,080.00
|
| Selling & Marketing
Expenses |
$2.10 M
|
$352,860.00
|
-$52,560.00
|
| Selling, General &
Administrative Expenses |
$9.65 M
|
$2.00 M
|
$17,520.00
|
| Other Expenses |
$6,473.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$9.65 M |
$2.00 M |
$17,520.00 |
| Cost And Expenses |
$9.95 M |
$2.00 M |
$17,520.00 |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$6,473.00 |
$181.00 |
| Depreciation &
Amortization |
$24,889.00
|
$3,863.00
|
$70,080.00
|
| EBITDA |
-$9.19 M
|
-$1.99 M
|
-$17,520.00
|
| EBITDA Ratio |
-12.57 |
-222.36 |
0 |
| Operating Income Ratio
|
-12.6
|
-222.8
|
0
|
| Total Other
Income/Expenses Net |
$6,473.00
|
-$6,473.00
|
-$181.00
|
| Income Before Tax |
-$9.21 M |
-$2.00 M |
-$17,701.00 |
| Income Before Tax Ratio
|
-12.59
|
-223.52
|
0
|
| Income Tax Expense |
$1.00 |
-$224,622.00 |
-$70,080.00 |
| Net Income |
-$9.21 M |
-$2.00 M |
-$17,701.00 |
| Net Income Ratio |
-12.59 |
-223.52 |
0 |
| EPS |
-0.43 |
-0.12 |
-0.001 |
| EPS Diluted |
-0.43 |
-0.12 |
-0.001 |
| Weighted Average Shares
Out |
$21.42 M
|
$17.32 M
|
$17.32 M
|
| Weighted Average Shares
Out Diluted |
$21.42 M
|
$17.32 M
|
$17.32 M
|
| Link |
|
|
|
